Ajanta Pharma Shares Complete Fundamental Analysis
Originally published: 06/04/2020 07:34
Publication number: ELQ-60103-1
View all versions & Certificate
certified

Ajanta Pharma Shares Complete Fundamental Analysis

Ajanta Pharma Shares Complete Fundamental Analysis

Description
Ajanta pharma focuses mostly on 4 major healthcare categories in India which include cardiology, dermatology, ophthalmology and pain management. They have a 270+ product basket and are driven by first to market philosophy. The other segment is exporting to emerging markets like Africa and other Asian countries. The export business is generally focused on generic drugs.

The company operates in the speciality and generic drug industry. The market dominance is determined by R&D and distribution network. Ajanta Pharma has 3000+ Medical representatives along with 15+ manufacturing facilities in India and Mauritius.

It competes with other large companies like Sun Pharma, Dr Reddy Laboratories and Biocon. These companies have better R&D facilities and a larger distribution network.

The Model covers all the major fundamental aspects of Ajanta Pharma Ltd over the ten year period. The model is easy to edit and update for the future years as well. It includes:
1. Growth Ratios
2. Profitability Ratios
3. Cash Flow Ratios
4. Liquidity and Solvency Ratios
5. Efficiency Ratios
6. Valuation Ratios
7. ROE (Du Pont Analysis)
8. Common Size analysis
9. Enterprise Valuation
10. Financial Strength Analysis

Further Qualitative analysis is also done considering these factors and ratings have been assigned.

This Best Practice includes
1 Microsoft Excel Model +1 Microsoft Word Document

Acquire nonprofit license for $3.50

Add to cart

Add to bookmarks

Discuss

Further information

The aim is to provide a thorough outlook into the company's financial position. This will help the students in projects and also the Investors who are looking to do their own due diligence before investing in the Indian Stock Markets.

Equity Research, Fundamental Analysis, Valuation, Long Term Investing


0.0 / 5 (0 votes)

please wait...